AbCellera Biologics ABCL

$ 2.77 1.65%

Quarterly report 2024-Q3
added 11-04-2024

AbCellera Biologics Financial Statements 2011-2024 | ABCL

Annual Financial Statements AbCellera Biologics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	1.53 B	2.54 B	2.4 B	6 B	-	-	-	-	-	-	-	-	-
Shares	289 M	285 M	276 M	159 M	-	-	-	-	-	-	-	-	-
Historical Prices	5.28	8.91	8.71	37.7	-	-	-	-	-	-	-	-	-
Net Income	-146 M	159 M	153 M	119 M	-2.21 M	309 K	-	-	-	-	-	-	-
Revenue	38 M	485 M	375 M	233 M	11.6 M	8.83 M	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-237 M	217 M	204 M	156 M	-4.12 M	-	-	-	-	-	-	-	-
Interest Expense	6.78 M	-4.04 M	-6.08 M	-6.81 M	-209 K	-	-	-	-	-	-	-	-
EBITDA	-213 M	244 M	219 M	158 M	-738 K	1.76 M	-	-	-	-	-	-	-
Operating Expenses	275 M	269 M	171 M	77.1 M	14 M	7.99 M	-	-	-	-	-	-	-
General and Administrative Expenses	61 M	55.5 M	41.8 M	11.9 M	2.75 M	2.15 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement AbCellera Biologics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	295 M	294 M	293 M	295 M	289 M	289 M	288 M	290 M	285 M	285 M	284 M	283 M	279 M	272 M	270 M	269 M	153 M	152 M	152 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-51.1 M	-36.9 M	-40.6 M	-	-28.6 M	-30.5 M	-40.1 M	-	26.6 M	-6.78 M	169 M	-	-21.4 M	-2.32 M	117 M	-	-2.69 M	6.7 M	-2.09 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	6.51 M	7.32 M	9.95 M	-	6.6 M	10.1 M	12.2 M	-	101 M	45.9 M	317 M	-	5.51 M	27.6 M	203 M	-	9.36 M	11.2 M	4.66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-93.7 M	-93.5 M	-54.9 M	-	-54.9 M	-51.4 M	-64.9 M	-	37.7 M	-8.4 M	225 M	-	-28.1 M	-7.03 M	158 M	-	-1.77 M	-854 K	-2.12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	17.9 M	32.2 M	-1.53 M	-	2.05 M	-1.97 M	3.59 M	-	1.15 M	-1.44 M	665 K	-	-1.26 M	314 K	265 K	-	-2.26 M	-293 K	-1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-89.9 M	-90.1 M	-50 M	-	-51.8 M	-48.4 M	-59.4 M	-	42.9 M	-3.51 M	229 M	-	-24.4 M	-3.51 M	161 M	-	-1.73 M	39 K	-1.55 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	100 M	101 M	64.8 M	-	61.5 M	61.4 M	77.1 M	-	63.6 M	54.3 M	91.6 M	-	33.6 M	34.7 M	44.7 M	-	11.1 M	12.1 M	6.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	19.1 M	20.2 M	17.4 M	-	14.4 M	15.5 M	15.1 M	-	13.8 M	14.4 M	14.3 M	-	11.3 M	11.2 M	6.42 M	-	2.97 M	1.5 M	1.65 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency